Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: A double-blind, placebo-controlled trial

Benjamin Morasco, Jennifer Loftis, David W. Indest, Samantha Ruimy, John W. Davison, Bradford Felker, Peter Hauser

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background: Approximately one-third of patients undergoing interferon-α (IFN-α) therapy for treatment of the hepatitis C virus (HCV) develop major depression, which decreases functioning and may lead to the reduction or discontinuation of treatment. Objective: The authors examined the efficacy of citalopram in preventing IFN-α-induced depression in HCV patients. Method: This was a randomized, controlled trial comparing citalopram with placebo in 39 HCV patients. Results: The rate of IFN-α-induced depression in the sample was 15.4% (6/39). Randomization to citalopram did not decrease the statistical likelihood of developing IFN-α-induced depression (10.5% for citalopram vs. 20.0% for placebo). Conclusion: Citalopram does not prevent depression onset; however, an empirically-supported treatment recommendation for IFN-α-induced depression includes monitoring depressive symptoms throughout antiviral therapy and initiating psychiatric treatment at the initial signs of depression.

Original languageEnglish (US)
Pages (from-to)401-408
Number of pages8
JournalPsychosomatics
Volume51
Issue number5
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Hepatitis C
Antidepressive Agents
Antiviral Agents
Citalopram
Placebos
Depression
Interferons
Hepacivirus
Therapeutics
Therapy
Controlled
Placebo
Antidepressants
Random Allocation
Psychiatry
Randomized Controlled Trials
Virus

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Applied Psychology

Cite this

Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy : A double-blind, placebo-controlled trial. / Morasco, Benjamin; Loftis, Jennifer; Indest, David W.; Ruimy, Samantha; Davison, John W.; Felker, Bradford; Hauser, Peter.

In: Psychosomatics, Vol. 51, No. 5, 09.2010, p. 401-408.

Research output: Contribution to journalArticle

Morasco, Benjamin ; Loftis, Jennifer ; Indest, David W. ; Ruimy, Samantha ; Davison, John W. ; Felker, Bradford ; Hauser, Peter. / Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy : A double-blind, placebo-controlled trial. In: Psychosomatics. 2010 ; Vol. 51, No. 5. pp. 401-408.
@article{28d78d52ef82449aa07611113f592e15,
title = "Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: A double-blind, placebo-controlled trial",
abstract = "Background: Approximately one-third of patients undergoing interferon-α (IFN-α) therapy for treatment of the hepatitis C virus (HCV) develop major depression, which decreases functioning and may lead to the reduction or discontinuation of treatment. Objective: The authors examined the efficacy of citalopram in preventing IFN-α-induced depression in HCV patients. Method: This was a randomized, controlled trial comparing citalopram with placebo in 39 HCV patients. Results: The rate of IFN-α-induced depression in the sample was 15.4{\%} (6/39). Randomization to citalopram did not decrease the statistical likelihood of developing IFN-α-induced depression (10.5{\%} for citalopram vs. 20.0{\%} for placebo). Conclusion: Citalopram does not prevent depression onset; however, an empirically-supported treatment recommendation for IFN-α-induced depression includes monitoring depressive symptoms throughout antiviral therapy and initiating psychiatric treatment at the initial signs of depression.",
author = "Benjamin Morasco and Jennifer Loftis and Indest, {David W.} and Samantha Ruimy and Davison, {John W.} and Bradford Felker and Peter Hauser",
year = "2010",
month = "9",
doi = "10.1176/appi.psy.51.5.401",
language = "English (US)",
volume = "51",
pages = "401--408",
journal = "Psychosomatics",
issn = "0033-3182",
publisher = "American Psychiatric Publishing Inc.",
number = "5",

}

TY - JOUR

T1 - Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy

T2 - A double-blind, placebo-controlled trial

AU - Morasco, Benjamin

AU - Loftis, Jennifer

AU - Indest, David W.

AU - Ruimy, Samantha

AU - Davison, John W.

AU - Felker, Bradford

AU - Hauser, Peter

PY - 2010/9

Y1 - 2010/9

N2 - Background: Approximately one-third of patients undergoing interferon-α (IFN-α) therapy for treatment of the hepatitis C virus (HCV) develop major depression, which decreases functioning and may lead to the reduction or discontinuation of treatment. Objective: The authors examined the efficacy of citalopram in preventing IFN-α-induced depression in HCV patients. Method: This was a randomized, controlled trial comparing citalopram with placebo in 39 HCV patients. Results: The rate of IFN-α-induced depression in the sample was 15.4% (6/39). Randomization to citalopram did not decrease the statistical likelihood of developing IFN-α-induced depression (10.5% for citalopram vs. 20.0% for placebo). Conclusion: Citalopram does not prevent depression onset; however, an empirically-supported treatment recommendation for IFN-α-induced depression includes monitoring depressive symptoms throughout antiviral therapy and initiating psychiatric treatment at the initial signs of depression.

AB - Background: Approximately one-third of patients undergoing interferon-α (IFN-α) therapy for treatment of the hepatitis C virus (HCV) develop major depression, which decreases functioning and may lead to the reduction or discontinuation of treatment. Objective: The authors examined the efficacy of citalopram in preventing IFN-α-induced depression in HCV patients. Method: This was a randomized, controlled trial comparing citalopram with placebo in 39 HCV patients. Results: The rate of IFN-α-induced depression in the sample was 15.4% (6/39). Randomization to citalopram did not decrease the statistical likelihood of developing IFN-α-induced depression (10.5% for citalopram vs. 20.0% for placebo). Conclusion: Citalopram does not prevent depression onset; however, an empirically-supported treatment recommendation for IFN-α-induced depression includes monitoring depressive symptoms throughout antiviral therapy and initiating psychiatric treatment at the initial signs of depression.

UR - http://www.scopus.com/inward/record.url?scp=77957328857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957328857&partnerID=8YFLogxK

U2 - 10.1176/appi.psy.51.5.401

DO - 10.1176/appi.psy.51.5.401

M3 - Article

C2 - 20833939

AN - SCOPUS:77957328857

VL - 51

SP - 401

EP - 408

JO - Psychosomatics

JF - Psychosomatics

SN - 0033-3182

IS - 5

ER -